Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, and Others), Drug Class (Plasma-Derived Coagulation Factor Concentrates Market and Others), Treatment (Desmopressin, Hormone Replacement Therapy), and Region-Forecast till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Bleeding disorders Treatment Market, by Type

6.1 Introduction

6.2 Hemophilia A

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.3 Hemophilia B

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.4 Von Willebrand Disease (vWD)

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.5 Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

Chapter 7. Global Bleeding disorders Treatment Market, by Drug Class

7.1 Introduction

7.2 Plasma-Derived Coagulation Factor Concentrates Market

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.3 Global Recombinant Coagulation Factor Concentrate Market

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.4 Global Others Bleeding Disorders Treatment Market

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

Chapter 8. Global Bleeding disorders Treatment Market, by Treatment

8.1 Introduction

8.2 Desmopressin (DDAVP)

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.3 Hormone Replacement Therapy

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.4 Contraceptives

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.5 Anti-Fibrinolytic/Clot-Stabilizing Drugs

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.6 Fibrin Sealants

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.6 Drugs applied to cuts

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.6 Pipeline Analysis (Phase I, Phase II and Phase III Clinical Trials)

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

Chapter 9. Global Bleeding disorders Treatment Market, by End-Users

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.3 Clinics

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.4 Research Institutes

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9.5 Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

Chapter 10. Global Bleeding disorders Treatment Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Shire Plc

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Bayer Pharmaceuticals

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

10.2.5 SWOT Analysis

12.3 Novo Nordisk A/S

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Pfizer Inc.

12.4.1 Company Overview

12.4.2 Technology/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Biogen Idec

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 CSL Behring

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Grifols

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Octapharma

12.8.1 Overview

12.8.2 Type/ Technology Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Sun Pharmaceutical Industries Ltd.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 BDI Pharma

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Ferring Pharmaceuticals

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Others

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

Chapter 13. MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Bleeding Disorders Treatment Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Bleeding disorders Treatment Synopsis, 2022–2030

Table 2 Global Bleeding disorders Treatment Estimates and Forecast, 2022–2030 (USD Billion)

Table 3 Global Bleeding disorders Treatment Market by Region, 2022–2030 (USD Billion)

Table 4 Global Bleeding disorders Treatment Market by Type, 2022–2030 (USD Billion)

Table 5 Global Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 6 Global Bleeding disorders Treatment Market by Treatment, 2022–2030 (USD Billion)

Table 7 Global Bleeding disorders Treatment Market End-users, 2022–2030 (USD Billion)

Table 8 North America: Bleeding disorders Treatment Market by Type, 2022–2030 (USD

Billion)

Table 9 North America: Bleeding disorders Treatment Market by Drug Class, 2022–2030 (USD Billion)

Table 10 North America: Bleeding disorders Treatment Market by Treatment, 2022–2030 (USD Billion)

Table 11 North America: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 12 US: Bleeding disorders Treatment Market by Type, 2022–2030 (USD Billion)

Table 13 US: Bleeding disorders Treatment Market by Drug Class, 2022–2030 (USD Billion)

Table 14 US: Bleeding disorders Treatment Market by Treatment, 2022–2030 (USD Billion)

Table 15 US: Bleeding disorders Treatment Market by End-users, 2022–2030 (USD Billion)

Table 16 Canada: Bleeding disorders Treatment Market by Type, 2022–2030 (USD Billion)

Table 17 Canada: Bleeding disorders Treatment Market by Drug Class, 2022–2030 (USD Billion)

Table 18 Canada: Bleeding disorders Treatment Market by Treatment, 2022–2030 (USD Billion)

Table 19 Canada: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 20 South America: Bleeding disorders Treatment Market by Type, 2022–2030 (USD Billion)

Table 21 South America: Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 22 South America: Bleeding disorders Treatment by Treatment, 2022–2030 (USD Billion)

Table 23 South America: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 24 Europe: Bleeding disorders Treatment by Type, 2022–2030 (USD Billion)

Table 25 Europe: Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 26 Europe: Bleeding disorders Treatment Market, by Treatment, 2022–2030 (USD Billion)

Table 27 Europe: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 28 Western Europe: Bleeding disorders Treatment by Type, 2022–2030 (USD Billion)

Table 29 Western Europe: Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 30 Western Europe: Bleeding disorders Treatment by Treatment, 2022–2030 (USD Billion)

Table 31 Western Europe: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 32 Eastern Europe: Bleeding disorders Treatment by Type, 2022–2030 (USD Billion)

Table 33 Eastern Europe Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 34 Eastern Europe Bleeding disorders Treatment by Treatment, 2022–2030 (USD Billion)

Table 35 Eastern Europe: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 36 Asia-Pacific: Bleeding disorders Treatment by Type, 2022–2030 (USD Billion)

Table 37 Asia-Pacific: Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 38 Asia-Pacific: Bleeding disorders Treatment by Treatment, 2022–2030 (USD Billion)

Table 39 Asia-Pacific: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Table 40 Middle East & Africa: Bleeding disorders Treatment by Type, 2022–2030 (USD Billion)

Table 41 Middle East & Africa Bleeding disorders Treatment by Drug Class, 2022–2030 (USD Billion)

Table 42 Middle East & Africa: Bleeding disorders Treatment Market, by Treatment, 2022–2030 (USD Billion)

Table 43 Middle East & Africa: Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Bleeding disorders Treatment

Figure 3 Segmentation Market Dynamics for Global Bleeding disorders Treatment

Figure 4 Global Bleeding disorders Treatment Industry Market Share, by Type, 2022

Figure 5 Global Bleeding disorders Treatment by End-users, 2022–2030 (USD Billion)

Figure 6 Global Bleeding disorders Treatment Market Share, by Region, 2022

Figure 7 North America: Bleeding disorders Treatment Market Share, by Country, 2022

Figure 8 Europe: Bleeding disorders Treatment Market Share, by Country, 2022

Figure 9 Asia-Pacific: Bleeding disorders Treatment Market Share, by Country, 2022

Figure 10 Middle East & Africa: Bleeding disorders Treatment Market Share, by Country, 2022

Figure 11 Global Bleeding disorders Treatment: Company Market Share Analysis, 2022 (%)

Figure 12 Shire Plc.: Key Financials

Figure 13 Shire Plc: Segmental Revenue

Figure 14 Shire Plc: Geographical Revenue

Figure 15 Bayer Pharmaceuticals: Key Financials

Figure 16 Bayer Pharmaceuticals: Segmental Revenue

Figure 17 Bayer Pharmaceuticals: Geographical Revenue

Figure 18 Novo Nordisk A/S: Key Financials

Figure 19 Novo Nordisk A/S: Segmental Revenue

Figure 20 Novo Nordisk A/S: Geographical Revenue

Figure 21 Pfizer Inc.: Key Financials

Figure 22 Pfizer Inc.: Segmental Revenue

Figure 23 Pfizer Inc.: Geographical Revenue

Figure 24 Biogen Idec: Key Financials

Figure 25 Biogen Idec: Segmental Revenue

Figure 26 Biogen Idec: Geographical Revenue

Figure 27 CSL Behring: Key Financials

Figure 28 CSL Behring: Segmental Revenue

Figure 29 CSL Behring: Geographical Revenue

Figure 30 Grifols: Key Financials

Figure 31 Grifols: Segmental Revenue

Figure 32 Grifols: Geographical Revenue

Figure 33 Octapharma: Key Financials

Figure 34 Octapharma: Segmental Revenue

Figure 35 Octapharma: Geographical Revenue

Figure 36 Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 37 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 38 Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 39 BDI Pharma: Key Financials

Figure 40 BDI Pharma: Segmental Revenue

Figure 41 BDI Pharma: Geographical Revenue

Figure 42 Ferring Pharmaceuticals: Key Financials

Figure 43 Ferring Pharmaceuticals: Segmental Revenue

Figure 44 Ferring Pharmaceuticals: Geographical Revenue

Figure 45 Others: Key Financials

Figure 46 Others: Segmental Revenue

Figure 47 Others: Geographical Revenue